**Introduction**

The predominant acute presentations of COVID-19 are respiratory, but neurological manifestations have been recognized as an important component of the disease, even in cases without respiratory symptoms (2-5). The neurological manifestations associated with COVID-19 range from mild to critical, affect adults and children and can present both during and after acute COVID-19 infection. Reported neurological signs, symptoms or syndromes in the acute phase include headache, dizziness, impaired taste or smell, delirium, agitation, stroke, seizures, coma, meningoencephalitis and Guillain-Barré syndrome (6, 7). Consequences in the post-acute phase are also emerging, as either persisting or newly developing signs and symptoms (post-COVID-19 condition); these include headache, problems with smell or taste, cognitive impairment, confusion, fatigue, difficulty concentrating, sleep disturbances and neuropsychiatric symptoms (8, 9).

COVID-19 disproportionately affects people with pre-existing neurological disorders. Chronic neurological disorders were found to be independently associated with increased mortality in hospitalized COVID-19 patients (hazard ratio [HR]: 2.13; 95% confidence interval [CI]: 1.38–3.28) (10). Individuals with pre-existing neurological conditions have been affected by disruptions to routine care, delayed care because of concerns about infectious risks and disruptions to supply chains for medicines and resultant stock-outs (11).

This scientific brief provides a comprehensive overview of the relationship between neurology and COVID-19 and covers what is currently known about:

- the acute neurological manifestations of COVID-19
- the neurological sequelae associated with post-COVID-19 condition
- the risk of infection, severe illness and mortality from COVID-19 for people with pre-existing neurological conditions
- the extent of disruptions to neurological services caused by the pandemic and mitigation strategies to address these disruptions
- emerging evidence for neurological complications following COVID-19 vaccination.

The target audience for this document includes health care providers, researchers, policy-makers and other stakeholders interested in the evidence relating to neurology and COVID-19. The aim is to increase awareness and recognition of the associated neurological aspects of COVID-19 to improve care and mitigation responses, particularly in low-resource settings.

**Methods**

This scientific brief is based on the evidence that emerged from systematic or rapid reviews and meta-analyses commissioned by WHO (14); WHO pulse surveys (15); WHO’s rapid assessment on services for mental, neurological and substance use (MNS) disorders (16) and other relevant publications.

---

Review of the evidence

Acute neurological manifestations of COVID-19

To assess the types and frequencies of reported neurological manifestations associated with COVID-19, WHO assisted with a systematic review and meta-analysis involving data from 145,721 patients with acute COVID-19 infections derived from 350 case series (17). COVID-19 infection was confirmed by real-time reverse-transcription polymerase chain reaction (RT-PCR) detection, high-throughput sequencing, SARS-CoV-2 viral culture in throat swab specimens, SARS-CoV-2 antibody detection in blood samples or SARS-CoV-2 viral culture in throat swab specimens. Most patients (n=129,786, 89%) included in the review were hospitalized.

A total of 23 acute neurological symptoms (Table 1) and 14 neurological diagnoses (Table 2) were reported in the literature. Up to one third (n=48,059) of COVID-19 patients experienced some type of neurological manifestation, and 1 in 50 developed a stroke. In COVID-19 patients aged over 60 years, the most frequent neurological manifestation was acute confusion/delirium (pooled prevalence: 34%; 95% CI: 23–46%).

Table 1. Pooled prevalence of neurological symptoms included in the meta-analysis (17)

<table>
<thead>
<tr>
<th>Variables</th>
<th>Number of studies</th>
<th>Pooled events</th>
<th>Pooled sample size</th>
<th>Pooled prevalence (%)</th>
<th>95% CI (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Corticospinal tract signs*</td>
<td>2</td>
<td>128</td>
<td>198</td>
<td>65</td>
<td>58–71</td>
</tr>
<tr>
<td>Agitation</td>
<td>3</td>
<td>145</td>
<td>468</td>
<td>45</td>
<td>3–93</td>
</tr>
<tr>
<td>Fatigue</td>
<td>169</td>
<td>14,121</td>
<td>45,766</td>
<td>32</td>
<td>30–35</td>
</tr>
<tr>
<td>Myalgia or fatigue</td>
<td>22</td>
<td>619</td>
<td>2,246</td>
<td>31</td>
<td>25–37</td>
</tr>
<tr>
<td>Taste impairment</td>
<td>38</td>
<td>2,934</td>
<td>12,631</td>
<td>21</td>
<td>15–29</td>
</tr>
<tr>
<td>Myalgia</td>
<td>207</td>
<td>12,183</td>
<td>59,821</td>
<td>20</td>
<td>18–23</td>
</tr>
<tr>
<td>Smell impairment</td>
<td>51</td>
<td>4,647</td>
<td>30,925</td>
<td>19</td>
<td>13–25</td>
</tr>
<tr>
<td>Smell or taste impairment</td>
<td>14</td>
<td>518</td>
<td>3,100</td>
<td>18</td>
<td>10–28</td>
</tr>
<tr>
<td>Headache</td>
<td>202</td>
<td>8,609</td>
<td>51,969</td>
<td>13</td>
<td>12–15</td>
</tr>
<tr>
<td>Headache and dizziness</td>
<td>9</td>
<td>676</td>
<td>3,520</td>
<td>12</td>
<td>8–17</td>
</tr>
<tr>
<td>Acute confusion/delirium</td>
<td>19</td>
<td>2,318</td>
<td>23,921</td>
<td>11</td>
<td>7–16</td>
</tr>
<tr>
<td>Disturbance of consciousness</td>
<td>25</td>
<td>693</td>
<td>15,129</td>
<td>7</td>
<td>5–10</td>
</tr>
<tr>
<td>Dizziness</td>
<td>46</td>
<td>809</td>
<td>13,473</td>
<td>7</td>
<td>5–8</td>
</tr>
<tr>
<td>Tinnitus</td>
<td>5</td>
<td>30</td>
<td>884</td>
<td>5</td>
<td>1–10</td>
</tr>
<tr>
<td>Vision impairment</td>
<td>10</td>
<td>126</td>
<td>2,904</td>
<td>4</td>
<td>1–9</td>
</tr>
<tr>
<td>Hearing impairment</td>
<td>6</td>
<td>20</td>
<td>819</td>
<td>3</td>
<td>1–5</td>
</tr>
<tr>
<td>Sensory impairment</td>
<td>4</td>
<td>23</td>
<td>1,082</td>
<td>2</td>
<td>1–5</td>
</tr>
<tr>
<td>Cognitive impairment</td>
<td>3</td>
<td>22</td>
<td>1,131</td>
<td>2</td>
<td>0–5</td>
</tr>
<tr>
<td>Cranial nerve palsy</td>
<td>3</td>
<td>7</td>
<td>463</td>
<td>2</td>
<td>0–8</td>
</tr>
<tr>
<td>Hemiplegia/paresis</td>
<td>2</td>
<td>5</td>
<td>467</td>
<td>2</td>
<td>0–10</td>
</tr>
<tr>
<td>Neuralgia</td>
<td>7</td>
<td>41</td>
<td>3,183</td>
<td>1</td>
<td>0–3</td>
</tr>
<tr>
<td>Seizure</td>
<td>15</td>
<td>127</td>
<td>15,467</td>
<td>1</td>
<td>0–2</td>
</tr>
<tr>
<td>Ataxia</td>
<td>5</td>
<td>25</td>
<td>2,266</td>
<td>1</td>
<td>0–2</td>
</tr>
</tbody>
</table>

CI: confidence interval.

* Corticospinal tract signs are diffuse hyperreflexia, ankle clonus and bilateral extensor plantar reflexes.

For all ages, the likelihood of experiencing acute confusion/delirium, stroke, seizure and movement disorders increased with increasing severity of COVID-19, but these associations were not statistically significant. Smell and taste impairments were significantly associated with non-severe COVID-19 (odds ratio [OR]: 0.44; 95% CI: 0.28–0.68 and OR: 0.62; 95% CI: 0.42–0.91, respectively). In COVID-19 patients aged over 60 years, the presence of any neurological manifestations was associated with significantly increased mortality (OR: 1.80; 95% CI: 1.11–2.91).
Table 2. Pooled prevalence of neurological diagnoses included in the meta-analysis (17)

<table>
<thead>
<tr>
<th>Variables</th>
<th>Number of studies</th>
<th>Pooled events</th>
<th>Pooled sample size</th>
<th>Pooled prevalence (%)</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>Neuropsychiatric disorders</td>
<td>3</td>
<td>243</td>
<td>1,293</td>
<td>24</td>
<td>2–61</td>
</tr>
<tr>
<td>Skeletal muscle injury</td>
<td>4</td>
<td>111</td>
<td>1,545</td>
<td>5</td>
<td>1–12</td>
</tr>
<tr>
<td>Myopathy</td>
<td>3</td>
<td>55</td>
<td>5,736</td>
<td>2</td>
<td>0–4</td>
</tr>
<tr>
<td>Stroke</td>
<td>29</td>
<td>664</td>
<td>43,024</td>
<td>2</td>
<td>1–2</td>
</tr>
<tr>
<td>Ischaemic stroke/TIA</td>
<td>29</td>
<td>527</td>
<td>43,024</td>
<td>1</td>
<td>1–2</td>
</tr>
<tr>
<td>Movement disorder</td>
<td>5</td>
<td>48</td>
<td>6,581</td>
<td>1</td>
<td>0–1</td>
</tr>
<tr>
<td>CIN/ polynephropathy</td>
<td>5</td>
<td>48</td>
<td>7,251</td>
<td>1</td>
<td>0–2</td>
</tr>
<tr>
<td>Status epilepticus</td>
<td>2</td>
<td>2</td>
<td>282</td>
<td>1</td>
<td>0–5</td>
</tr>
<tr>
<td>Haemorrhagic stroke</td>
<td>21</td>
<td>133</td>
<td>36,972</td>
<td>0.31</td>
<td>0.15–0.50</td>
</tr>
<tr>
<td>Encephalitis</td>
<td>4</td>
<td>8</td>
<td>4,658</td>
<td>0.30</td>
<td>0–1</td>
</tr>
<tr>
<td>Guillain-Barré syndrome</td>
<td>4</td>
<td>22</td>
<td>7,403</td>
<td>0.28</td>
<td>0–1</td>
</tr>
<tr>
<td>Parainfectious radiculitis</td>
<td>2</td>
<td>2</td>
<td>858</td>
<td>0.23</td>
<td>0–1</td>
</tr>
<tr>
<td>Cerebral venous thrombosis</td>
<td>2</td>
<td>4</td>
<td>14,573</td>
<td>0.12</td>
<td>0–2</td>
</tr>
<tr>
<td>PRES</td>
<td>3</td>
<td>6</td>
<td>4,311</td>
<td>0.12</td>
<td>0.02–0.27</td>
</tr>
</tbody>
</table>

CIN: critical illness myopathy; PRES: posterior reversible encephalopathy syndrome; TIA: transient ischaemic attack.

* Includes significant creatinine kinase elevation and rhabdomyolysis.

b Includes CIN, PRES and TIA.

Limitations

The overall risk of bias was assessed as being low for most studies (n=296, 85%) but studies with higher risk of bias yielded higher prevalence estimates. Also, for most outcomes the meta-analyses yielded a high degree of heterogeneity, indicating substantial clinical or methodological diversity, which in some instances rendered the pooling of data inappropriate.

There are gaps in the evidence for non-hospitalized patient cohorts because their data are rarely reported in the literature. The evidence gaps have implications for incidence, prevalence, duration and severity. Similarly, the timing of the onset of signs or symptoms is often not reported. Limitations in study design of included case series precluded the comparison between acute neurological manifestations caused by COVID-19 and the incidence of such manifestations in the general population. Finally, in the absence of well-designed cohort studies, there are insufficient data to definitively assert causality between these symptoms and COVID-19.

Neurological sequelae associated with post-COVID-19 condition

Complications following acute viral illnesses are well described (18, 19). Soon after the advent of the COVID-19 pandemic, longitudinal cohort studies started to assess long-term sequelae of COVID-19, including neurological manifestations. At the same time, patients began to connect with each other and report on prolonged symptoms of COVID-19. In response, WHO commissioned a rapid review of 28 published population-based, cohort or case-control studies. The review established specific new-onset neurological symptoms, signs or diagnoses occurring after the acute phase of COVID-19 that can be interpreted as complications of COVID-19; assessed specific neurological symptoms, signs or diagnoses that persist after the acute phase of COVID-19; and determined factors associated with these post-acute neurological manifestations.

Of the 28 studies, only two followed patients for up to 6 months. Pooling of information was not possible for methodological reasons. In a retrospective cohort of 1733 COVID-19 patients discharged from hospital, 19.6% (n=340) reported neurological manifestations after a median follow-up of 186 days (9). The complaints most commonly reported were fatigue or muscle weakness (63%; 1038/1655) and sleep difficulties (26%; 437/1655). Anxiety and depression were reported by 23% (367/1617) of patients and difficulty walking by 24% (103/423). The second prospective study followed 61 hospitalized COVID-19 patients with and without history of admission to an intensive care unit (ICU) (20).

Common complaints at discharge included amnestic dysfunction (30%; 18/61), dysexecutive syndrome (33%; 20/61), ataxia (11%, 7/61), and tetraparesis (18%; 11/61) (20).

Limitations

The evidence for long-term or newly emerging neurological complications after COVID-19 is limited, particularly in asymptomatic or non-hospitalized patients. Similarly, little is known about neurological sequelae in paediatric patients with conditions related to COVID-19, including multisystem inflammatory syndrome (MIS-C). Data from low- and middle-income countries are scarce, particularly in the post-acute phase. This has led to underreporting of neurological findings in the context of COVID-19 with reference to geography, ethnicity and sociocultural environment.

Methodological issues and study design flaws further reduce the strength of the current evidence because some studies have included in the control group asymptomatic patients who were not screened with molecular or serological tests to confirm or exclude SARS-CoV-2 infection. Screening methods and diagnostic protocols vary across studies, depending on the background of the local investigators, the diagnostic approach, the number and type of contacts during follow-up and, not least, attrition and patient compliance. In addition, studies were done under surge conditions, which led to incomplete diagnostic assessment.

The current understanding of neurological sequelae associated with post-COVID-19 condition is based mainly on patient reports; clinically relevant manifestations; and greater attention towards symptoms, signs and diseases that have been illustrated in previous reports. By contrast, information is limited on signs that can be documented only through testing, imaging or biochemical or pathological investigations.

Pre-existing neurological conditions and COVID-19

A range of pre-existing non-communicable diseases (NCDs) are associated with an increased risk of severe outcomes in COVID-19 (21). These include several neurological conditions such as stroke and dementia. People with certain pre-existing neurological conditions are more vulnerable to SARS-CoV-2 infection, experience exacerbations of their pre-existing disease (22) and have higher risks of severe outcomes and death (10, 23). To synthesize the growing evidence on this topic, WHO commissioned a rapid review of 26 articles from 12 countries across three continents, with a total of 379,947 COVID-19 patients, to establish the risk of infection, severe illness and mortality from COVID-19 for people with pre-existing neurological conditions.  

The rapid review found that certain pre-existing neurological diseases are associated with severity of COVID-19. The most prevalent were cerebrovascular disease and dementia/neurodegenerative diseases (pooled OR: 1.99; 95% CI: 1.81–2.18). Mortality was high among people with pre-existing neurological conditions (pooled OR: 1.74; 95% CI: 1.56–1.94).

Limitations

Risk of bias was deemed high for most articles, and the overall quality of studies using GRADE (Grading of Recommendations Assessment, Development and Evaluations) methodology was low; hence, the value of the current evidence is limited. Most studies on the relationship between SARS-CoV-2 and pre-existing neurological conditions are based on retrospective cohorts or case series, with few data from prospective studies. Future research will benefit greatly from the use of standardized definitions and reporting for comorbidities, neurological symptoms or diagnoses. Use of standardized case report forms – such as those published by WHO (25, 26) – can also contribute to the accuracy and reliability of data.

Disruptions to essential neurological services caused by the COVID-19 pandemic and mitigation strategies

Interruption of routine treatment and care, as well as supply chains for medications during the COVID-19 pandemic, present significant challenges for people with neurological conditions (11). According to the latest WHO Pulse survey on continuity of essential health services during the COVID-19 pandemic (27), 45% of 121 countries for which information was available still reported disruptions to services for MNS disorders in the first quarter of 2021. Likewise,
disruptions to rehabilitation services, a crucial aspect of neurological care, continue to be reported by 53% (of 89 countries). With respect to neurology-specific services, WHO’s rapid assessment of services for MNS disorders during the COVID-19 pandemic in mid-2020 (16) revealed that one in three of 98 countries closed down neurology inpatient units at least partly during the pandemic. Regarding service provision, surgeries for neurological disorders were disrupted in two-thirds of 130 countries for which information was available, and the management of emergency conditions such as status epilepticus was at least partially disrupted in 35% of the same 130 countries.

To better understand the extent of service disruption, its causes and mitigation strategies for neurological disorders in the context of COVID-19, WHO commissioned a rapid review of 369 articles, providing data on 210 419 patients from 105 countries (14).

Studies that investigated the extent of service disruption (n=188) described it as mild (n=40, 21%), moderate (n=131, 70%) or severe (n=10, 5%). The most frequently described reasons for service disruption across 240 studies were travel restrictions related to lockdown (n=196, 82%), closure of services or consultations as per health authority directive (n=157, 65%) and reduced outpatient volume due to patients not presenting (n=135, 56%). A total of 224 studies reported on mitigation strategies, with the most frequently reported strategies being telemedicine and other teleconsultation formats (n=184, 82%), novel dispensing approaches for medicines (n=116, 52%) and redirection of patients (n=95, 42%).

Limitations

To date, most of the data on service disruption have been derived from high- and middle-income countries, with information from low-income countries lacking. Similarly, evidence of the effectiveness and acceptability of mitigation strategies to patients remains limited. In addition, the current published literature seems biased towards certain settings or types of services (e.g. outpatient, emergency or inpatient care). There are few reports on other areas that are crucial for treating people with chronic neurological conditions (e.g. neurorehabilitation). Going forward, more systematic evaluations and reporting of disruption of the whole spectrum of neurological services can provide a more comprehensive picture.

Neurological complications following COVID-19 vaccination

There is a low risk following COVID-19 vaccination of neurological complications including Bell’s palsy (28), cerebral venous sinus thrombosis (CVST) and possibly Guillain-Barré syndrome (29). However, the risk of such complications is substantially lower than the risks associated with infection with SARS-CoV-2 (30, 31). Since March 2021, cases of thromboses associated with thrombocytopenia have been reported in patients vaccinated with the Oxford-AstraZeneca ChAdOx1-S and Johnson & Johnson (J&J) Janssen Ad26.COV2.S COVID-19 vaccines. Evaluation of the cases by national and international bodies concluded that there was a plausible causal link between these two adenovirus-vectored vaccines and CVST (32-34), based on the temporal association with vaccination and an increased incidence when compared with expected baseline rates of CVST (35-42). WHO has provided guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination against COVID-19 (43).

Overall knowledge gaps

Current evidence suggests that SARS-CoV-2 can affect the nervous system. Multiple and probably overlapping mechanisms have been proposed for the neurological manifestations; they include hypoxia, cytokine storm, post-infectious autoimmune responses, hypercoagulability, neurologic complications of severe systemic illness and potential direct neurotropism. Questions remain regarding the characteristics, timing and severity of neurological manifestations of COVID-19, including the pathophysiological mechanisms through which SARS-CoV-2 affects the nervous system. As more data emerge, associations of specific neurological disorders with COVID-19 will be further clarified – as has been seen, for example, with Guillain-Barré syndrome (29). Prospective data, as well as biomarker and neuropathological studies, are needed on the short- and long-term neurological sequelae.

Existing reports on the association between COVID-19 and most neurological manifestations are flawed by selection and information bias, and available data reflect the spectrum of neurological manifestations in patients with the more severe COVID-19 cases. Neurological signs or symptoms occurring during the acute phase of COVID-19 infection cannot easily be disentangled from those with onset in the post-acute phase, and follow-up data are scarce, particularly for subclinical findings such as cognitive impairment.
Other gaps in the literature include a lack of clarity on the interplay between pre-existing neurological disease and other underlying comorbidities such as hypertension and diabetes. Studies in this area were hospital-based and biased to people with more severe symptoms, making the findings difficult to generalize to people based in the community or having only mild symptoms. Understanding the impact of neurological conditions requires the inclusion of diverse populations from a variety of social backgrounds.

Guidance is also needed for studies evaluating the disruption or the efficacy of mitigation strategies for care. Efforts should be made to harmonize the methods in this area of research and to enhance the comparability between studies and over time. In addition, funding for and progress in neurological research and training have been affected by the pandemic, owing to the temporary suspension of research projects or postponement or cancellation of fellowships, which need to be re-established as soon as possible (44).

Implications for further research

Well-designed case–control and cohort studies are needed to understand which patients are most vulnerable to neurological manifestations in the acute and post COVID-19 condition and to understand causality related to COVID-19. Series of patients with neurological conditions need to be compared to patients without neurological conditions. Use of case report forms (CRFs) such as WHO’s post-COVID-19 condition CRF (45) is encouraged to standardize data collection. Future research directions should include more “bottom-up” evidence-gathering efforts; for example, international surveys of neurological associations such as one recently undertaken by the European Federation of Neurological Associations (EFNA) with support from members of the WHO Neurology and COVID-19 Global Forum (46).

Conclusion

A wide spectrum of acute and post-acute neurological manifestations associated with COVID-19 have been reported across the globe. Clinicians and health care workers should be aware of such presentations and complications even in the absence of respiratory symptoms. Disruptions in access to essential neurological services and availability of essential medications for people with pre-existing neurological conditions can be detrimental; hence, mitigation strategies such as remote technology and telemedicine alternatives should be judiciously employed. The COVID-19 pandemic continues to have an impact on neurological health, service delivery, research and training while widening existing disparities worldwide. Recognizing and addressing these factors will provide opportunities to improve neurological care worldwide.

Plans for updating

WHO continues to monitor the situation closely for any changes that may affect this scientific brief. Should any factors change, WHO will issue a further update. Otherwise, this scientific brief will expire 1 year after the date of publication.

Acknowledgements

In response to the ongoing global pandemic and increasing reports of neurological manifestations in COVID-19, the World Health Organization (WHO) established the Neurology and COVID-19 Global Forum in June 2020. This collaborative network of international stakeholders currently includes more than 70 clinicians, researchers and technical experts from 25 countries. The forum focuses on COVID-19 neurological surveillance, acute clinical care, follow-up, long-term impact and the provision of essential services. We thank the members of the WHO Neurology and COVID-19 Global Forum for their contribution to this scientific brief. The development of this scientific brief has also benefited from strong collaborations with other neurology and COVID-19 groups (12, 13). External reviewers of this document included members of this Global Forum.

We would like to especially thank the following WHO Neurology and COVID-19 Global Forum members for their specific contributions to this document: Ricardo Allegri (Universidad de Buenos Aires, Argentina), Ettore Beghi (Istituto di Ricerche Famacologiche Mario Negri IRCCS Milano, Italy), Maria Lucia Brito Ferreira (Hospital da Restauração, Brazil), Chahnez Chafni Triki (Hedi Chaker Hospital, Tunisia), Mashina Chomba (University Teaching Hospitals, Zambia), Sherry Chou (University of Pittsburgh, United States of America [USA]), David Garcia-Azorin (Hospital Clinico Universitario Valladolid, Spain), Alla Guekht (Moscow Research and Clinical Center for Neuropsychiatry, Russian Federation), MatildeLeonardi (Italian WHO-Collaborating Centre Research Branch, National Neurological Society, Italy), Benedict Michael (University of Liverpool, United Kingdom of Great Britain and Northern Ireland), Shubham Misra (All India Institute of Medical Sciences,
Neurology and COVID-19: Scientific brief

India), Kameshwar Prasad (All India Institute of Medical Sciences, India), Deanna Saylor (University Teaching Hospitals, Zambia), James Sejvar (United States Centers for Disease Control and Prevention, USA), Tom Solomon (University of Liverpool, United Kingdom of Great Britain and Northern Ireland), Kiran Thakur (Columbia University, USA) and Andrea Winkler (Technical University of Munich, Germany), Greta Wood (University of Liverpool, United Kingdom of Great Britain and Northern Ireland).

Declaration of interests: All members of the forum were asked to complete the WHO declaration of interest forms which were reviewed and it was confirmed that none had any conflicts of interest requiring a management plan.

WHO: Neerja Chowdhary, Tarun Dua, Kavitha Kolappa, Nicoline Schiess, Katrin Seeher (Brain health unit, Department of Mental Health and Substance Use), Janet Diaz (Clinical Management Response COVID-19, Health Care Readiness Unit), Jill Farrington (WHO Regional Office for Europe, Non-communicable Diseases) Wouter de Groote (Rehabilitation Programme, SDR Unit, Department of Non-communicable Diseases) and Yuka Sumi (Ageing and health, Department of Maternal, Newborn, Child and Adolescent Health and Ageing).

Related WHO publications

COVID-19 clinical management: living guidance (47). This guidance document is intended for clinicians caring for COVID-19 patients during all phases of their disease (i.e. from screening to discharge). This update has been expanded to meet the needs of front-line clinicians. It promotes a multidisciplinary approach to care for patients with COVID-19, including those with mild, moderate, severe or critical disease.

Expanding our understanding of post-COVID-19 condition: report of a WHO webinar – 9 February 2021 (47). There has been an increase in the number and scope of research activities on post-COVID-19 condition by public health agencies, academics, patient-led research groups and other stakeholders. Currently, progress in diagnosis, treatment and management has been limited by a lack of consensus on the clinical case definition and limited understanding of the clinical characterization during the recovery period and associated pathophysiology. With the goal of advancing this field by bringing together stakeholders from around the world, WHO organized this and other webinars to expand the knowledge of the post-COVID-19 condition.

Policy brief: COVID-19 and the need for action on mental health (48). This United Nations (UN) policy brief outlines the impact of the pandemic on mental health, including a box specifically highlighting the links between COVID-19 and neurology. Implementation of recommended actions by national decision-makers will help to minimize and address the mental and brain health consequences of this pandemic.

The impact of COVID-19 on mental, neurological and substance use services (16). This report of a survey completed by 130 countries during the period June–August 2020 established for the first time the extent of disruption to mental, neurological and substance use services; the types of services that have been disrupted; and how countries are adapting to overcome these challenges.

Maintaining essential health services: operational guidance for the COVID-19 context interim guidance (49). This document recommends practical actions that countries can take at national, subregional and local levels to reorganize and safely maintain access to high-quality, essential health services in the pandemic context. It also outlines sample indicators for monitoring essential health services and describes considerations on when to stop and restart services as COVID-19 transmission recedes and surges.

Guidance for clinical case management of thrombosis with thrombocytopenia syndrome (TTS) following vaccination to prevent coronavirus disease (COVID-19) (43). CVST is a neurological condition and is a common presentation of TTS. TTS has emerged as a new adverse event following immunization in individuals vaccinated with COVID-19 non-replicant adenovirus-vectored vaccines (AstraZeneca COVID-19 ChAdOx-1 vaccine and J&J Janssen COVID-19 Ad26.COV2-S vaccine). WHO has issued this interim emergency guidance to increase awareness about TTS in the context of COVID-19 vaccination, and to assist health care providers with the assessment and management of potential TTS cases.
Neurology and COVID-19: Scientific brief

References


© World Health Organization 2021. Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence.